Evidence map›Paper›PMID 24475331›Full record

ArticleIranian journal of microbiology2013

EspA-Intimin chimeric protein, a candidate vaccine against Escherichia coli O157:H7.

Hamid Sedighian Rad, Seyed Latif Mousavi, Iraj Rasooli, Jafar Amani, Moohamad Reza Jalali Nadooshan

Open access · greenAbstract read
In one paragraph

Article in Iranian journal of microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Treatment Strategies for Infections With Shiga Toxin-ProducingFrontiers in cellular and infection microbiology · 2020
    Review
  3. Genetic Diversity ofIranian journal of pathology · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hamid Sedighian RadApplied Microbiology Research Center, Baqiyatallah Medical Science University, Tehran.
Seyed Latif MousaviDepartment of Biology, Faculty of Basic Sciences, Shahed University, Tehran, Iran.
Iraj RasooliDepartment of Biology, Faculty of Basic Sciences, Shahed University, Tehran, Iran.
Jafar AmaniApplied Microbiology Research Center, Baqiyatallah Medical Science University, Tehran.
Moohamad Reza Jalali NadooshanDepartment of Pathology, Faculty of Medical Sciences, Shahed University, Tehran, Iran.
Shahed University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveEnterohemorrhagic Escherichia coli (EHEC) O157:H7 is an important enteric pathogen in human causing bloody or nonbloody diarrhea, which may be complicated by hemolytic uremic syndrome (HUS). Cattle are an important reservoir of EHEC. This research aims at vaccination with a divalent chimer protein composed of EspA120 and Intimin 282 and its preventive effect of EHEC O157 colonization in mice rectal epithelium. MATERIALS AND

methodsA divalent recombinant EspA-Intimin (EI) protein containing EspA120 and Intimin280 attached with a linker was amplified from a trivalent construct and cloned in pET-28a (+) vector. The immunization was conducted in mice after expression and purification of the recombinant EI (rEI).

resultsMice subcutaneously immunized with rEI, elicited significant rEI specific serum IgG antibodies and showed significantly decreased E.coli O157:H7 shedding compared to the control group.

conclusionThe chimeric recombinant protein induced strong humoral response as well as protection against oral challenges with live E.coli O157:H7.

Indexed as

Chimeric vaccineEnterohemorrhagic Escherichia coliEspAIntimin

Identifiers

PMID24475331
PMCPMC3895562
OpenAlexW2101429589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.